An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. Derived from Melanotan II research.

Is PT-141 FDA approved?

Yes, PT-141 is FDA approved. FDA Approved - HSDD in premenopausal women

What are the side effects of PT-141?

Reported side effects of PT-141 include: Nausea (40% - most common), Facial flushing (20%), Injection site reactions, Headache, Transient blood pressure increase, Skin hyperpigmentation with frequent use, Vomiting, Fatigue, FDA approved (Vyleesi) for HSDD in women.

What is the typical dosing for PT-141?

FDA-approved dosing. Common doses observed in research: 1.75 mg (FDA approved for women), Research doses for men varied. Duration: As needed, at least 45 min before activity. Administration: Subcutaneous injection (autoinjector available).

Sexual Health

PT-141

Also known as: Bremelanotide, Vyleesi

FDA Approved

Popular For

Sexual desire, erectile dysfunction, low libido

Key Facts: PT-141

Category: Sexual Health
FDA Status: FDA Approved
Clinical Status: FDA Approved - HSDD in premenopausal women
Administration: Subcutaneous injection (autoinjector available)
Typical Dose: 1.75 mg as needed
Frequency: As needed, at least 45 min before activity
Evidence Level: FDA Approved
Duration: As needed, at least 45 min before activity

Also Known As

Bremelanotide, Vyleesi

Mechanism of Action

PT-141 activates melanocortin receptors, particularly MC4R in the central nervous system. Unlike PDE5 inhibitors that work on blood flow, PT-141 works through the brain's sexual arousal pathways, affecting desire and arousal centrally.

Research Summary

FDA approved June 2019 for women with HSDD based on trials with 1,247 subjects. 2024 male observational study (21 men) showed efficacy for ED and sexual dysfunction, particularly in those who failed PDE5 inhibitors. Phase II male trials ongoing with Phase III planned for 2025. Works through central nervous system pathways rather than peripheral vascular mechanisms.

Clinical Status:FDA Approved - HSDD in premenopausal women

Trial Progress:FDA Approved

Pre

III

FDA

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

1.75 mg as needed

Range

0.5-2 mg per dose

Frequency

As needed, at least 45 min before activity

FDA-approved dose is 1.75 mg. Not for daily use - max 8 doses per month. Can cause nausea and flushing.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

FDA-approved dosing

Doses from Studies

1.75 mg (FDA approved for women)

FDA Approved Labeling - Prescribed dose ↗

Research doses for men varied

FDA Approved Labeling - Prescribed dose ↗

Duration

As needed, at least 45 min before activity

Administration

Subcutaneous injection (autoinjector available)

Timing & Administration

Best Time to Take

1-2 hours before sexual activity

As needed, max once per 24 hours

Food Recommendation

With or without food

Why This Timing?

PT-141 (Bremelanotide) takes 45-60 minutes to work. Timing before anticipated activity is optimal.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Nausea (40% - most common)
●Facial flushing (20%)
●Injection site reactions
●Headache
●Transient blood pressure increase
●Skin hyperpigmentation with frequent use
●Vomiting
●Fatigue
●FDA approved (Vyleesi) for HSDD in women

References

Related Peptides

Peptides commonly compared with PT-141 or used in similar applications.

Melanotan II

Research

A synthetic analog of alpha-melanocyte stimulating hormone (α-MSH). Known for inducing skin tanning and having effects on libido and sexual function.

Sexual Health

Semaglutide

FDA

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Oxytocin

FDA

A naturally occurring peptide hormone crucial for social bonding, childbirth, and lactation. Being studied for autism, anxiety, and social disorders.

Hormonal

MK-677

Clinical Trials

An orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.

Growth Hormone

Selank

Clinical Trials

A synthetic peptide derived from tuftsin, an immunomodulatory peptide. Approved in Russia for anxiety and nootropic effects. Known for anxiolytic properties without sedation.

Cognitive

How to Use PT-141 PT-141 Alternatives Compare with Similar Browse All Peptides

Looking for a trusted vendor?

Pro members get access to verified vendors with quality standards & exclusive discount codes.

View Verified Vendors

PRO

Want updates on PT-141 research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides